αEβ7 Integrin Identifies Subsets of Pro-Inflammatory Colonic CD4+ T Lymphocytes in Ulcerative Colitis.
暂无分享,去创建一个
J. Mansfield | J. Egen | A. Hayday | J. Eastham‐Anderson | L. Diehl | C. Lamb | J. Kirby | D. Gibbons | M. Keir | P. Irving | A. Long | G. Tew | M. Price | G. O'boyle | David E. J. Jones | S. O’Byrne | G. W. Tew
[1] T. Barrett,et al. p53 mediates TNF-induced epithelial cell apoptosis in IBD. , 2012, The American journal of pathology.
[2] Graham M Lord,et al. Complement regulator CD46 temporally regulates cytokine production by conventional and unconventional T cells , 2010, Nature Immunology.
[3] E. Sgouroudis,et al. ICOS-Dependent Homeostasis and Function of Foxp3+ Regulatory T Cells in Islets of Nonobese Diabetic Mice , 2012, The Journal of Immunology.
[4] E. Butcher,et al. Lymphocyte trafficking and regional immunity. , 1999, Advances in immunology.
[5] L. Cosmi,et al. Human interleukin 17–producing cells originate from a CD161+CD4+ T cell precursor , 2008, The Journal of experimental medicine.
[6] J. Buer,et al. Developmental Stage, Phenotype, and Migration Distinguish Naive- and Effector/Memory-like CD4+ Regulatory T Cells , 2004, The Journal of experimental medicine.
[7] L. Cosmi,et al. Phenotypic and functional features of human Th17 cells , 2007, The Journal of experimental medicine.
[8] T. Nomura,et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. , 2009, Immunity.
[9] C. Drachenberg,et al. Critical Role for CD103+CD8+ Effectors in Promoting Tubular Injury following Allogeneic Renal Transplantation , 2005, The Journal of Immunology.
[10] M. Pekalski,et al. Renal allograft rejection: the contribution of chemokines to the adhesion and retention of alphaE(CD103)beta7 integrin-expressing intratubular T cells. , 2008, Molecular immunology.
[11] C. Drachenberg,et al. TGF-β–dependent CD103 expression by CD8+ T cells promotes selective destruction of the host intestinal epithelium during graft-versus-host disease , 2005, The Journal of experimental medicine.
[12] W. Tremaine,et al. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. , 1987, The New England journal of medicine.
[13] P. Kilshaw. Alpha E beta 7. , 1999, Molecular pathology : MP.
[14] B. Rocha,et al. A unique subpopulation of CD4+ regulatory T cells controls wasting disease, IL‐10 secretion and T cell homeostasis , 2003, European journal of immunology.
[15] D. Podolsky,et al. Expression of transforming growth factors alpha and beta in colonic mucosa in inflammatory bowel disease. , 1996, Gastroenterology.
[16] J. Mansfield,et al. A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis , 2012, Gut.
[17] T. Huizinga,et al. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells , 2007, European journal of immunology.
[18] Jay K Kolls,et al. The Th17 pathway and inflammatory diseases of the intestines, lungs, and skin. , 2013, Annual review of pathology.
[19] B. Müller-Myhsok,et al. Role of the novel Th17 cytokine IL‐17F in inflammatory bowel disease (IBD): Upregulated colonic IL‐17F expression in active Crohn's disease and analysis of the IL17F p.His161Arg polymorphism in IBD , 2008, Inflammatory bowel diseases.
[20] J. Mansfield,et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial , 2014, The Lancet.
[21] C. Griscelli,et al. A monoclonal antibody (HML‐1) defining a novel membrane molecule present on human intestinal lymphocytes , 1987, European journal of immunology.
[22] T. Giese,et al. Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. , 2005, Gastroenterology.
[23] T. Yi,et al. In vivo-activated CD103+CD4+ regulatory T cells ameliorate ongoing chronic graft-versus-host disease. , 2007, Blood.
[24] R. D. Hatton,et al. Transforming growth factor-β induces development of the TH17 lineage , 2006, Nature.
[25] A. Andoh,et al. Increased expression of interleukin 17 in inflammatory bowel disease , 2003, Gut.
[26] S. Targan,et al. Natalizumab induction and maintenance therapy for Crohn's disease. , 2005, The New England journal of medicine.
[27] S. Devine,et al. CD103 Deficiency Prevents Graft-versus-Host Disease but Spares Graft-versus-Tumor Effects Mediated by Alloreactive CD8 T Cells , 2011, PloS one.
[28] E. Shevach,et al. GARP (LRRC32) is essential for the surface expression of latent TGF-β on platelets and activated FOXP3+ regulatory T cells , 2009, Proceedings of the National Academy of Sciences.
[29] E. Major. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. , 2010, Annual review of medicine.
[30] Stefan Schreiber,et al. Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis. , 2016, Gastroenterology.
[31] P. Rutgeerts,et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. , 2013, The New England journal of medicine.
[32] K. Ley,et al. Role of beta7 integrins in intestinal lymphocyte homing and retention. , 2009, Current molecular medicine.
[33] Ting Wang,et al. Color image segmentation using pixel wise support vector machine classification , 2011, Pattern Recognit..
[34] R. D. Hatton,et al. Interplay between the TH17 and TReg cell lineages: a (co-)evolutionary perspective , 2009, Nature Reviews Immunology.
[35] F. Powrie,et al. Essential role for CD103 in the T cell–mediated regulation of experimental colitis , 2005, The Journal of experimental medicine.
[36] M. V. D. van den Brink,et al. Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine. , 2006, Blood.
[37] Alf Hamann,et al. Expression of the integrin αEβ7 identifies unique subsets of CD25+ as well as CD25− regulatory T cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[38] B. Ludviksson,et al. Administration of mAb Against αEβ7 Prevents and Ameliorates Immunization-Induced Colitis in IL-2−/− Mice , 1999, The Journal of Immunology.
[39] R. D. Hatton,et al. The Th17 family: flexibility follows function , 2013, Immunological reviews.
[40] L. Cosmi,et al. Evidence for a cross-talk between human neutrophils and Th17 cells. , 2010, Blood.
[41] A. Hayday,et al. Epithelial decision makers: in search of the 'epimmunome' , 2010, Nature Immunology.
[42] S. Bartlett,et al. The epithelial cell-specific integrin, CD103 (alpha E integrin), defines a novel subset of alloreactive CD8+ CTL. , 1997, Journal of immunology.
[43] H. Herfarth,et al. Blocking MAdCAM-1 in vivo reduces leukocyte extravasation and reverses chronic inflammation in experimental colitis , 2004, International Journal of Colorectal Disease.
[44] K. Papadakis,et al. Role of beta7 integrin and the chemokine/chemokine receptor pair CCL25/CCR9 in modeled TNF-dependent Crohn's disease. , 2008, Gastroenterology.
[45] M. Sans,et al. VCAM-1, but Not ICAM-1 or MAdCAM-1, Immunoblockade Ameliorates DSS-Induced Colitis in Mice , 2000, Laboratory Investigation.
[46] A. Huisman,et al. Automatic Nuclei Segmentation in H&E Stained Breast Cancer Histopathology Images , 2013, PloS one.
[47] Sarah L. Brown,et al. Efficient colonic mucosal wound repair requires Trem2 signaling , 2009, Proceedings of the National Academy of Sciences.
[48] S. Targan,et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. , 2007, Gastroenterology.
[49] Markus F. Neurath,et al. Cytokines in inflammatory bowel disease , 2014, Nature Reviews Immunology.
[50] G. Lichtenstein. Progressive Multifocal Leukoencephalopathy After Natalizumab Therapy for Crohn's Disease , 2006 .
[51] D. Beier,et al. Mucosal T lymphocyte numbers are selectively reduced in integrin alpha E (CD103)-deficient mice. , 1999, Journal of immunology.
[52] Kristin Stephens,et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. , 2013, The New England journal of medicine.
[53] Herman Waldmann,et al. Plasticity of Foxp3(+) T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells. , 2012, Immunity.
[54] M. Neurath,et al. Blockade of αEβ7 integrin suppresses accumulation of CD8+ and Th9 lymphocytes from patients with IBD in the inflamed gut in vivo , 2016, Gut.